Current treatments for chronic hepatitis B are suboptimal. In the search for improved therapies, we compared the efficacy and safety of pegylated interferon alfa plus lamivudine, pegylated interferon ...

HBsAg decline at week 24 and baseline HBsAg levels are better predictors of functional cure than novel virologic markers, while on-treatment HBV RNA and HBeAg levels and dynamic changes are the most ...

Much of the liver injury in HBV infection reflects host immune response rather than a direct cytopathic effect of the virus. During the course of chronic HBV infection, biochemical dysfunction may be ...

Is a liver biopsy necessary in a patient who is hepatitis B surface antigen (HBsAg)-positive, hepatitis B e antigen (HBeAg)-negative, has normal liver enzymes, and has detectable hepatitis B virus ...

The presence of hepatitis B e antigen (HBeAg) in serum indicates active viral replication in hepatocytes. HBeAg is thus a surrogate marker for the presence of hepatitis B virus DNA. We conducted a ...

Two cross-sectional, one validation cohort, and meta-analyses were used to explore the relationship between HBV replication and liver inflammation. Spearman analysis, multiple linear regression, and ...

Elecsys® HBeAg quant is an immunoassay that can be used as an early marker of acute hepatitis B infection, as well as an indicator of chronic active hepatitis in combination with other laboratory ...

Please provide your email address to receive an email when new articles are posted on . The cumulative probability of functional cure was 14.53% at a mean age of 25.75 years. The annual cure rate was ...

More than half of patients who suffer from chronic hepatitis B have the e antigen (HBeAg)-negative form of the disease. Even after many years of antiviral treatment with nucleos(t)ide analogues (NUC), ...

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...